Novavax Inc said its covid vaccine was effective at up to 89.3% to prevent the corona virus in a test conducted in the United Kingdom on Thursday and according to preliminary analysis to be almost as effective at protecting against the highly infectious variant first discovered in Britain Have received At the same time, a mid-stage trial of the vaccine in South Africa, where the new virus version is becoming a major problem, saw 60% effectiveness in people who did not have HIV.
Novavax shares witnessed a growth of 34%. It is also being said that this speeding was seen after the release of the results of the test, after the information about its first case of the South African version arrived in America. Novavax is already stocking the vaccine at six operating manufacturing locations, and it is learned that it is expecting a total of 8 plants in 7 countries to produce 2 billion doses per year. , Which also includes the Serum Institute of India. According to the information received, the UK trial, which has enrolled 15,000 people between the ages of 18 and 84, is being applied to be used in the UK, EU and other countries. Approval of the Novavax vaccine will be most welcome in Europe as it is in a conflict situation over Pfizer / BioNotech and AstraZeneca PLC receiving fewer vaccines than expected.
It has also been said that Pune-based Serum Institute has tied up with pharmaceutical company Novavax Inc. to produce its potential covid vaccine for India and other countries. According to the agreement, Serum Institute is preparing 2 billion doses of Novavax every year. Serum has also tied up with US company Codagenix to produce and distribute its Corona vaccine.
Also Read:-
No COVID-19 death in Nepal in last 24 hours
New strain of corona grows in America, death rate increased rapidly
Number of new strain of coronavirus cases increases worldwide